Skip Navigation

CAFs Combination of Atezolizumab and pirfenidone in Second-line and Beyond NSCLC: a Phase I/II study

Brief Summary

Type:
Lung Cancers

Study Type:
Treatment

Phase:
I/II

ClinicalTrials.gov Identifier:
NCT04467723

Study #:
STUDY00146333

Start Date:
May 17, 2022

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04467723

View Complete Trial Details & Eligibility at ClinicalTrials.gov